Author | Pharmaceutical Press, the Royal Pharmaceutical Society's knowledge business |
---|---|
Country | United Kingdom |
Language | British English |
Subject | Medicine, Pharmacy |
Genre | Medicines Information |
Publisher | BMJ, Pharmaceutical Press, Royal College of Paediatrics and Child Health, Neonatal & Paediatric Pharmacists Group [1] |
Publication date | September 2022 (2022-2023 edition) |
Media type | Paperback print, digital online, smartphone app |
Pages | 1287 |
ISBN | 978-0-85711-429-7 |
OCLC | 1338670038 |
Website | www.bnf.org |
BNF for Children (BNFC) is the standard UK paediatric reference for prescribing and pharmacology.
It contains a wide range of information and advice on prescribing for children - from newborn to adolescence. The entries are classified by group of drug, giving cautions for use, side effects, indications and dose for most of the drugs available for children in the UK National Health Service. It also includes information on the unlicensed uses of certain drugs. Though published in and for the United Kingdom, the vast bulk of the clinical information will apply in any country.
The BNFC is jointly published annually by BMJ (owned by the BMA), Pharmaceutical Press (owned by the RPS), Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group. [1] The principal contributors are acknowledged in the front pages.
It is overseen by the BNFC Paediatric Formulary Committee [2] and edited by a team of pharmacists. [3]
The BNF for Children developed from the British National Formulary (BNF), which prior to 2005 had provided information on the treatment of children, with the doses largely determined by calculations based on the body weight of the child. The guidance was provided by pharmacists and doctors whose expertise was in the care of adults.
This was an anomaly, [4] as in relation to responses to medicines, the difference between a newborn and a sixteen-year-old is greater than the difference between a sixteen-year-old and a sixty-year-old. Starting in 2002, Prof Martin Kendall, [5] [6] then chairman of the BNF Joint Formulary Committee worked to get things changed.
The UK Department of Health (now the DHSC) agreed to fund the BNFC, as it does the BNF, to ensure that NHS clinicians can have up-to-date information in their pockets.
The first edition was published in 2005, with George Rylance [7] chairing the Paediatric Formulary Committee and Dinesh Mehta as the first executive editor. Anne, the Princess Royal attended the launch on 14 July.
The BNFC is published annually, but electronic updates [8] are produced monthly. The current 2022-2023 edition was published in September 2022.
Though not aimed at the general public, the BNFC, like the BNF, is available for purchase. [9]
It is provided to NHS staff - usually through their employer, but may be accessed online through MedicinesComplete. [10]
The app is available through the usual app stores. [11] [12]
The British National Formulary (BNF) is a United Kingdom (UK) pharmaceutical reference book that contains a wide spectrum of information and advice on prescribing and pharmacology, along with specific facts and details about many medicines available on the UK National Health Service (NHS). Information within the BNF includes indication(s), contraindications, side effects, doses, legal classification, names and prices of available proprietary and generic formulations, and any other notable points. Though it is a national formulary, it nevertheless also includes entries for some medicines which are not available under the NHS, and must be prescribed and/or purchased privately. A symbol clearly denotes such drugs in their entry.
A prescription, often abbreviated ℞ or Rx, is a formal communication from a physician or other registered healthcare professional to a pharmacist, authorizing them to dispense a specific prescription drug for a specific patient. Historically, it was a physician's instruction to an apothecary listing the materials to be compounded into a treatment—the symbol ℞ comes from the first word of a medieval prescription, Latin recipere, that gave the list of the materials to be compounded.
A prescription drug is a pharmaceutical drug that is permitted to be dispensed only to those with a medical prescription. In contrast, over-the-counter drugs can be obtained without a prescription. The reason for this difference in substance control is the potential scope of misuse, from drug abuse to practicing medicine without a license and without sufficient education. Different jurisdictions have different definitions of what constitutes a prescription drug.
The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body, in England, of the Department of Health and Social Care, that publishes guidelines in four areas:
The pregnancy category of a medication is an assessment of the risk of fetal injury due to the pharmaceutical, if it is used as directed by the mother during pregnancy. It does not include any risks conferred by pharmaceutical agents or their metabolites in breast milk.
Phenobarbital, also known as phenobarbitone or phenobarb, sold under the brand name Luminal among others, is a medication of the barbiturate type. It is recommended by the World Health Organization (WHO) for the treatment of certain types of epilepsy in developing countries. In the developed world, it is commonly used to treat seizures in young children, while other medications are generally used in older children and adults. In developed countries it is used for veterinary purposes. It may be used intravenously, injected into a muscle, or taken by mouth. The injectable form may be used to treat status epilepticus. Phenobarbital is occasionally used to treat trouble sleeping, anxiety, and drug withdrawal and to help with surgery. It usually begins working within five minutes when used intravenously and half an hour when administered by mouth. Its effects last for between four hours and two days.
The British Pharmacopoeia (BP) is the national pharmacopoeia of the United Kingdom. It is an annually published collection of quality standards for medicinal substances in the UK, which is used by individuals and organisations involved in pharmaceutical research, development, manufacture and testing.
Tizanidine, sold under the brand name Zanaflex among others, is an alpha-2 (α2) adrenergic receptor agonist, similar to clonidine, that is used to treat muscle spasticity due to spinal cord injury, multiple sclerosis, and spastic cerebral palsy. Effectiveness appears similar to baclofen or diazepam. It is taken by mouth.
The NHS treatments blacklist is an informal name for a list of medicines and procedures which will not be funded by public money except in exceptional cases. These include but are not limited to procedures which the National Institute for Health and Care Excellence (NICE) has ruled of limited effectiveness and particular brand name medicines. In 2017 there was a proposal for 3,200 over-the-counter (OTC) drugs to be restricted and 18 procedures to be added to the list. This generated some controversy amongst doctors with some arguing that OTC should be blacklisted instead, and others believing the move did not take into account individual patient needs.
The Yellow Card Scheme is the United Kingdom's system for collecting information on suspected adverse drug reactions (ADRs) to medicines. The scheme allows the safety of the medicines and vaccines that are on the market to be monitored.
Pharmaceutical policy is a branch of health policy that deals with the development, provision and use of medications within a health care system. It embraces drugs, biologics, vaccines and natural health products.
Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat type 2 diabetes in conjunction with exercise and diet. It is generally less preferred than metformin and sulfonylureas as an initial treatment. It is taken by mouth.
A formulary is a list of pharmaceutical drugs, often decided upon by a group of people, for various reasons such as insurance coverage or use at a medical facility. Traditionally, a formulary contained a collection of formulas for the compounding and testing of medication. Today, the main function of a prescription formulary is to specify particular medications that are approved to be prescribed at a particular hospital, in a particular health system, or under a particular health insurance policy. The development of prescription formularies is based on evaluations of efficacy, safety, and cost-effectiveness of drugs.
Irish Medicines Formulary (IMF) is a medicines reference for doctors, nurses, pharmacists and dentists, providing medicines information which is medico-legally relevant in Ireland. It is published in online and print formats, and lists original brands, branded generics and pure generic prescription medicines.
Pharmacy in the United Kingdom has been an integral part of the National Health Service since it was established in 1948. Unlike the rest of the NHS, pharmacies are largely privately provided apart from those in hospitals, and even these are now often privately run.
David Robert Harvey was a British paediatrician and considered by his peers to be a champion of the less privileged. Harvey was most notable for developing the training of neonatal medicine doctors at a time when the speciality had no official recognition. Harvey was homosexual and never afraid to disclose it, even at the beginning of his career, when homophobia was more prominent.
British Association of Perinatal Medicine known as BAPM, is a charitable organization that was founded in Bristol in 1976 that is most notable for being a pressure group to advance the standards of perinatal care within the United Kingdom by a dedicated core of professional physicians who are accredited by examination.
The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing is a pocket-size medical manual focusing on the most commonly prescribed medicines by the British National Health Service (NHS). It was first published by Churchill Livingstone, Elsevier, in 2014, revised in a second edition in 2018, and again in 2022 in a third edition. It is authored by four clinical pharmacologists from St George's Hospital, London; Andrew Hitchings, Dagan Lonsdale, Daniel Burrage and Emma Baker.